Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | OGG1 | O15527 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL342966 | 0.87 | GSK3B (0.48) | GSK3BSLC6A2SLC6A4SLC6A3CES2 | |
| SCHEMBL2853000 | 0.81 | KMT2A (0.48) | GSK3BSLC6A2SLC6A4SLC6A3CES2 | |
| SCHEMBL27986090 | 0.78 | GSK3B (0.43) | GSK3BSLC6A2SLC6A4SLC6A3CES2 | |
| SCHEMBL28003628 | 0.78 | TDP1 (0.50) | GSK3BSLC6A2SLC6A4SLC6A3CES2 | |
| SCHEMBL6313883 | 0.77 | GSK3B (0.42) | GSK3BSLC6A2SLC6A4SLC6A3CES2 | |
| SCHEMBL18994620 | 0.76 | SLC6A2 (0.49) | GSK3BSLC6A2SLC6A4SLC6A3CES2 | |
| SCHEMBL8861336 | 0.74 | GSK3B (0.50) | GSK3BSLC6A2SLC6A4SLC6A3CES2 | |
| SCHEMBL3033043 | 0.74 | SLC6A2 (0.47) | GSK3BSLC6A2SLC6A4SLC6A3CES2 | |
| SCHEMBL10620689 | 0.74 | ALDH1A1 (0.54) | HTTALDH1A1KMT2ASMN1; SMN2CA1 | |
| SCHEMBL29007609 | 0.73 | GSK3B (0.47) | GSK3BSLC6A2SLC6A4SLC6A3CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040039024-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2004-02-26 | — | — | US | claimed |
| EP-1150961-B1 | PYRAZOLECARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI SYNTHELABO (FR) | 2003-10-22 | — | — | EP | claimed |
| US-20020188007-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 2002-12-12 | — | — | US | claimed |
| US-20040039024-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2004-02-26 | — | — | US | disclosed |
| US-6645985-B2 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them, and method of treating | SANOFI (FR) | 2003-11-11 | — | — | US | disclosed |
| US-20020188007-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 2002-12-12 | — | — | US | disclosed |
| US-6432984-B1 | CANNABINOID RECEPTOR ANTAGONISTS; TREATMENT OF OBESITY, DRUG ADDICTION, ALCHOLISM, PSYCHOLOGICAL, AND EATING DISORDERS | SANOFI-SYNTHELABO (FR) | 2002-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039024-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | CNR1, CNR2, P2RY1 | GSK3B 3477/4885SLC6A2 3753/4885SLC6A4 1998/4885 |
| US-20020188007-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | CNR1, CNR2, P2RY1 | GSK3B 3477/4885SLC6A2 3753/4885SLC6A4 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.